Showing results (51-60 of 73) with videos related to
Sort By:
Pageof 8
British Journal of Cancer|October 17, 2022
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodulesXinyu Zhang, Zhuo Yu, Yaping Xu, et al.Cancer Research and Treatment|October 5, 2018
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 TrialXueying Li, He Huang, Bing Xu, et al.British Journal of Cancer|December 19, 2023
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancerBolin Chen, Wenxiu Yao, Xingya Li, et al.Nature Communications|March 11, 2022
Clinical and genomic features of Chinese lung cancer patients with germline mutationsWenying Peng, Bin Li, Jin Li, et al.Cancer|November 28, 2017
Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencingJacqueline F Wang, Xingxiang Pu, Xiaoshan Zhang, et al.Lancet (London, England)|May 29, 2026
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trialAnwen Xiong, Wenxiu Yao, Wei Zheng, et al.Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.Thoracic Cancer|October 21, 2022
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitorWenxian Wang, Qian Wang, Chunwei Xu, et al.Thoracic Cancer|November 29, 2022
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancerShirong Zhang, Wenxian Wang, Chunwei Xu, et al.Pageof 8